PTC Therapeutics (NASDAQ: PTCT) reported Q1 EPS of ($0.03), $0.43 better than the analyst estimate of ($0.46). Revenue for the quarter came in at $273 million versus the consensus estimate of $224.08 million.

GUIDANCE:

PTC Therapeutics sees FY2026 revenue of $1.08-1.18 billion, versus the consensus of $990.8 million.

For earnings history and earnings-related data on PTC Therapeutics (PTCT) click here.